Phase 2 N=8 Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
Heart Failure
Primary: Median Interval Change From Baseline in Peak VO2 — 3.90 mL/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers
Leg Ulcer · Varicose Ulcer
Primary: Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator's Direct Observation. — 1; 4; 3…
Phase 2 N=37 Vorinostat in Treating Patients With Acute Myeloid Leukemia
Adult Acute Erythroid Leukemia (M6) · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Confirmed Complete Response (CR) Rate — 0; 4.5 percentage of participants
Phase 2 N=233 To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
Tuberculosis
Primary: The Median Time to Sputum Culture Conversion — 57 Days
Phase 2 N=8 A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Hepatitis C Infection · HIV Infection
Primary: Number of Participants With Adverse Events — 8 participants
Phase 2 N=24 Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
Lung Cancer
Primary: Number of Evaluable Participants With Tumor Response — 5 participants
Phase 2 N=45 Effect of Electrical Stimulation (DC Polarization) to the Brain on Memory
Healthy
Primary: Verbal Memory — 8.625; 9; 8 Words recalled — p=>0.05
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 2 N=37 Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 16 percentage of participants
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 2 N=20 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Pleural Mesothelioma · Peritoneal Mesothelioma
Primary: Clinical Response Rate (PR+CR) — 0; 0 Participants
Phase 2 N=45 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer · Stage IIIA Ovarian Epithelial Cancer
Primary: Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR) — 2.5; 0; 15; 40 Percentage of Participants
Phase 2 N=45 Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Rate of Participants Achieving Complete Response or Partial Response to Therapy. — 6; 25; 0 participants
Phase 2 N=57 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-free Survival — .438; .292 proportion of participants